Elebsiran
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Elebsiran
- aln 81890 free acid
- ALN-81890 FREE ACID
- brii 835 vir 2218
- BRII-835 (VIR-2218)
- elebsiran
- Elebsiran
- elebsiran [INN]
- ELEBSIRAN [USAN]
- elebsiran inn
- elebsiran usan
- rna gm sp um sp gm um 2 deoxy 2 fluoro g cm 2 deoxy 2 fluoro a 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u um cm gm cm um um cm am cm am 3 2s 4r 1 29 2 acetylamino 2 deoxy β d galactopyranosyl oxy 14 14 bis 3 3 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino propyl amino 3 oxopropoxy methyl 1 12 19 25 tetraoxo 16 oxa 13 20 24 triazanonacos 1 yl 4 hydroxy 2 pyrrolidinyl methyl hydrogen phosphate complex with rna um sp 2 deoxy 2 fluoro g sp um gm am 3 3 9 de β d ribofuranosyl 9 2s 2 3 dihydroxypropyl a 2 5 gm 2 deoxy 2 fluoro c 2 deoxy 2 fluoro g am am gm um 2 deoxy 2 fluoro g cm 2 deoxy 2 fluoro a cm am cm sp um sp um 1 1
- RNA, (Gm-sp-Um-sp-Gm-Um-(2′-deoxy-2′-fluoro)G-Cm-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Um-Cm-Gm-Cm-Um-Um-Cm-Am-Cm-Am), 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)G-sp-Um-Gm-Am-(3′→3′)-[9-de-β-D-ribofuranosyl-9-[(2S)-2,3-dihydroxypropyl]]A-(2′→5′)-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)G-Am-Am-Gm-Um-(2′-deoxy-2′-fluoro)G-Cm-(2′-deoxy-2′-fluoro)A-Cm-Am-Cm-sp-Um-sp-Um) (1:1)
- vir 2218
- VIR 2218
- VIR 2218 [WHO-DD]
- vir 2218 who dd
- Vir-2218
- VIR-2218
- CAS registry numbers
- 2648009-64-5
- ChEMBL ID
- CHEMBL5315044
- FDA ingredient codes (UNII)
- W982Y6N4X7
- First in class
- No
- Orphan designation
- No
- Condition
- Virus Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Hepatitis D
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007304
- Subject identifier
- D003699
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004197
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007304
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005366
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005789
- Highest recorded phase
- 3
- NCT03672188
- NCT04412863
- NCT04507269
- NCT04749368
- NCT04856085
- NCT04891770
- NCT05612581
- NCT06092333
- NCT05461170
- NCT05844228
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- (3'-5'): G=U=G-U-G-C-A-C-U-U-C-G-C-U-U-C-A-C-A-R1 (5'-3'):U=U=C-A-C-A-C-G-U-G-A-A-G-C-G-A-A-G-U=G=U
Related records
Trials (18)
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
- A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
- Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
- Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
- Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
- Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
In development for (5)
- Chronic hepatitis B virus infection Phase 2
- Hepatitis B virus infection Phase 2
- Hepatitis D virus infection Phase 2
- Kidney disorder Phase 1
- Viral infectious disease Phase 2